Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Kucukzeybek, Yuksel ^a   Gul, Mustafa K ^a   Cengiz, Ercument ^a   Erten, Cigdem ^a   Karaca, Burcak ^a   Gorumlu, Gurbuz ^a   Atmaca, Harika ^b   Uzunoglu, Selim ^b   Karabulut, Bulent ^a   Sanli, Ulus A ^a   Uslu, Ruchan ^a  

^a EGE UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; DOCETAXEL; LYMPHOTOXIN BETA RECEPTOR; PROTEIN BIRC5; PROTEIN MCL 1; RETINOIC ACID; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; TAXOID; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; LYMPHOTOXIN BETA RECEPTOR; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TRETINOIN;

EID: 52949132303     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-37     Document Type: Article

References (30)

1. Cancer statistics. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
2. Abrogation of heat-shock protein (HSP) 70 expression induced cell growth inhibition and apoptosis in human androgen-independent prostate cancer cell line PC-3m. ZG Zhao QZ Ma CX Xu, Asian J Androl 2004 6 319 324 15546023
3. Chemistry and chemical biology of taxane anticancer agents. ML Miller I Ojima, Chem Rec 2001 1 195 211 10.1002/tcr.1008 11895119
4. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. DR Berthold GR Pond F Soban WR De M Eisenberger IF Tannock, J Clin Oncol 2008 26 242 245 10.1200/JCO.2007.12.4008 18182665
5. Overcoming multidrug resistance in taxane chemotherapy. R Geney M Ungureanu D Li I Ojima, Clin Chem Lab Med 2002 40 918 925 10.1515/CCLM.2002.161 12435109
6. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. D Petrylak, BJU Int 2005 96 Suppl 2 41 46 10.1111/j.1464-410X.2005. 05946.x 16359438
7. Retinoids as antitumor agents: A new age of biological therapy. JM Kurie WK Hong, Cancer Journal from Scientific American 1999 5 150 151 10367170
8. Retinoids in cancer chemoprevention. R Lotan, FASEB J 1996 10 1031 1039 8801164
9. Differential expression of nuclear retinoid receptors in normal and malignant prostates. Y Lotan XC Xu M Shalev R Lotan R Williams TM Wheeler TC Thompson D Kadmon, J Clin Oncol 2000 18 116 121 10623701
10. Retinoids in cancer therapy. MA Smith DR Parkinson BD Cheson MA Friedman, J Clin Oncol 1992 10 839 864 1569455
11. Vitamin A and apoptosis in prostate cancer. XK Zhang, Endocr Relat Cancer 2002 9 87 102 10.1677/erc.0.0090087 12121833
12. Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. K Koshiuka E Elstner E Williamson JW Said Y Tada HP Koeffler, Br J Cancer 2000 82 452 458 10.1054/bjoc.1999.0942 10646904
13. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. A Nehme P Varadarajan G Sellakumar M Gerhold H Niedner Q Zhang X Lin RD Christen, Br J Cancer 2001 84 1571 1576 10.1054/bjoc.2001.1818 11384110
14. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. SE Blutt EA Allegretto JW Pike NL Weigel, Endocrinology 1997 138 1491 1497 10.1210/en.138.4.1491 9075707
15. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. MJ Caliaro P Vitaux C Lafon I Lochon A Nehme A Valette P Canal R Bugat S Jozan, Br J Cancer 1997 75 333 340 9020476
16. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. TC Chou, Pharmacol Rev 2006 58 621 681 10.1124/pr.58.3.10 16968952
17. Survivin, versatile modulation of cell division and apoptosis in cancer. DC Altieri, Oncogene 2003 22 8581 8589 10.1038/sj.onc.1207113 14634620
18. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. K Fujise D Zhang J Liu ET Yeh, J Biol Chem 2000 275 39458 3965 10.1074/jbc.M006626200 10978339
19. The molecular basis and potential role of survivin in cancer diagnosis and therapy. DC Altieri, Trends Mol Med 2001 7 542 547 10.1016/S1471-4914(01) 02243-2 11733216
20. Survivin study: what is the next wave? F Li, J Cell Physiol 2003 197 8 29 10.1002/jcp.10327 12942537
21. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. C Adida C Recher E Raffoux MT Daniel AL Taksin P Rousselot F Sigaux L Degos DC Altieri H Dombret, Br J Haematol 2000 111 196 203 10.1046/j.1365-2141.2000.02328.x 11091201
22. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. C Adida C Haioun P Gaulard E Lepage P Morel J Briere H Dombret F Reyes J Diebold C Gisselbrecht G Salles DC Altieri TJ Molina, Blood 2000 96 1921 1925 10961895
23. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. S Kamihira Y Yamada Y Hirakata M Tomonaga K Sugahara T Hayashi N Dateki H Harasawa K Nakayama, Br J Haematol 2001 14 63 69 10.1046/j.1365-2141.2001.02902.x
24. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. C Adida D Berrebi M Peuchmaur M Reyes-Mugica DC Altieri, Lancet 1998 351 882 883 10.1016/S0140-6736(05)70294-4 9525374
25. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. RW Craig, Leukemia 2002 16 444 454 10.1038/sj.leu.2402416 11960321
26. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein suggests a unique role for Mcl-1 in control of programmed cell death in vivo. S Krajewski S Bodrug M Krajewska A Shabaik R Gascoyne K Berean JC Reed, Am J Pathol 1995 146 1309 1319 7778670
27. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. KJ Aichberger M Mayerhofer KV Gleixner MT Krauth A Gruze WF Pickl V Wacheck E Selzer L Mullauer H Agis C Sillaber P Valent, Blood 2007 109 3031 341 17110460
28. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. MA Degli-Esposti T Davis-Smith WS Din PJ Smolak RG Goodwin CA Smith, J Immunol 1997 158 1756 1762 9029113
29. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. M Lukashev D LePage C Wilson V Bailly E Garber A Lukashin M Lukashev D LePage C Wilson V Bailly E Garber A Lukashin A Ngam-ek W Zeng N Allaire S Perin X Xu K Szeliga K Wortham R Kelly C Bottiglio J Ding L Griffith G Heaney E Silverio W Yang M Jarpe S Fawell M Reff A Carmillo K Miatkowski J Amatucci T Crowell H Prentice W Meier SM Violette F Mackay D Yang R Hoffman JL Browning, Cancer Res 2006 66 9617 9624 10.1158/0008-5472.CAN-06-0217 17018619
30. Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor. H Winter NK van den Engel CH Poehlein RA Hatz BA Fox HM Hu, J Transl Med 2007 5 14 17355640 10.1186/1479-5876-5-14